Maven's MBO Fund II Backs Covestus to Acquire UltraDEX and Dentyl

December 9, 2025

Maven’s MBO Fund II, together with other Maven client funds, has committed up to £15 million to back Covestus, a Cheltenham-based consumer healthcare platform, to accelerate its buy-and-build strategy. The initial investment will support Covestus’s acquisition of two oral-care brands, UltraDEX and Dentyl, from Venture Life Group plc to strengthen its UK and international oral-care footprint.

Buyers
Maven's MBO Fund II, Other Maven client funds, Covestus
Targets
UltraDEX, Dentyl
Sellers
Venture Life Group plc
Platforms
Covestus
Location
Berkshire, United Kingdom
Transaction Type
Growth capital

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.